In a Honduran city, biotechs create gene therapy cocktails to fight aging
By Frankie Fattorini,
Pharmaceutical Technology
| 12. 02. 2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a clinical site in Próspera to study the cognitive and health benefits with its circular RNA therapy in a Phase I trial (NCT07216781), in addition to a site in Austin, Texas, where it is headquartered. Last year, the longevity-focused biotech Unlimited Bio got incorporated in the city. Its CEO Ivan Morgunov told Pharmaceutical Technology that Próspera’s lax regulations foster the company’s lofty goal to create a regimen of gene therapies and other treatments aimed at addressing what he sees as the problem of human ageing.
However, industry experts are not yet convinced. Fellow gene therapy developers question both the scientific plausibility of fighting ageing through combinatorial gene therapies and whether ageing can be pathologised at all. At the same time, it is unknown if such biotechs can gather data acceptable to regulatory agencies like the US Food and Drug Administration...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...